Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
CLEO Diagnostics Expands US Addressable Market for Pre-Surgical Ovarian Cancer Test
CLEO Diagnostics (ASX: COV) has used an analysis of insurance data to significantly expand the total addressable market in the US for its new pre-surgical ovarian cancer detection test.
Latest Stories
Imagion Biosystems Considers Lower Dosage Of Magsense Breast Cancer Imaging Agent For Phase 2 Trial
Imagion Biosystems (ASX: IBX) has received positive results on dosage tests in preparation for a Phase 2 clinical trial of HER2 breast cancer imaging agent MagSense.
EVE Health Appoints Medical Science Liaison to Drive Clinical Engagement
EVE Health Group (ASX: EVE) has appointed its first dedicated medical science liaison (MSL) to lead national medical education and prescriber engagement programs across Australia.
EVE Health Enters Commercial Rollout Phase for Dyspro and Libbo Following First Prescriptions and Purchase Orders
EVE Health Group (ASX: EVE) has reached several key milestones in its transition to commercial operations, achieving first patient prescriptions of its Dyspro cannabinoid-based gummy and submitting the initial purchase order for Libbo, an oral dissolving film for erectile dysfunction.
Algorae Pharmaceuticals Driving Expansion with Innovation and Commercialisation
Algorae Pharmaceuticals (ASX: 1AI) has reported a period of significant expansion as it broadens its operations to include complementary commercial activities. In the three months to end September, the company advanced its dual-track strategy of AI-driven innovation and pharmaceutical commercialisation, securing two landmark deals to expand its presence across Australia and New Zealand. Algorae also advanced […]
Genetic Signatures Reports Regional Success of EasyScreen Gastrointestinal Parasite Detection Kit
Genetic Signatures (ASX: GSS) has reported a strong start to the new financial year with the commercial success of its EasyScreen gastrointestinal parasite detection testing kit across all operating regions, and a 20% increase in sales for the quarter to $5.4 million. Revenue contributions came from new business with existing customers in Australia, which experienced […]
Algorae Pharmaceuticals Expands Commercial Footprint with New Cadila Partnership
Algorae Pharmaceuticals (ASX: 1AI) and private Indian company Cadila Pharmaceuticals have entered into a licence and supply agreement covering two new generic medicines for the Australian and New Zealand markets. The agreement will formalise an operational framework for the partnership and will see Algorae commence planning for Therapeutic Goods Administration (TGA) registration to enable commercialisation of […]
TrivarX to Acquire Stabl-Im Diagnostic Technology for Early Detection of Metastatic Brain Tumours
TrivarX (ASX: TRI) has announced plans to acquire novel Stabl-Im metastatic brain technology and associated stable isotope cancer diagnostic intellectual property from Australian company Nucleics. Stabl-Im represents a potential breakthrough in the safe and non-invasive detection of brain cancers and metastases using standard magnetic resonance imaging (MRI) equipment to visualise and monitor tumour growth without the […]
Biotron Announces $2.5 Million Capital Raising to Fund Sedarex Acquisition
Biotron (ASX: BIT) has announced the acquisition of unlisted company Sedarex Limited, the owner of SedRx — a patented next-generation general anaesthetic — alongside a $2.5 million capital raising to fund the transaction and advance development programs. The acquisition delivers Biotron a late-stage clinical asset supported by US Food and Drug Administration (FDA) and European Medicines […]
EVE Health Secures $1.1m Funding to Propel Dyspro and Libbo Product Launches
EVE Health Group (ASX: EVE) has received stong support from sophisticated and professional investors for a capital raising aimed at accelerating the commercial rollout of its lead pharmaceutical products Dyspro and Libbo. When the placement attracted bids in excess of the $1 million EVE initially sought, the company increased the offer to $1.1m, the maximum capacity […]
Dimerix Reports Positive Data Supporting Action3 Study of DMX-200 to Treat Kidney Disease
Dimerix (ASX: DXB) has received final data analysis from the international PARASOL collaboration that reinforces support for proteinuria-based endpoints in its pivotal Phase 3 Action3 study on DMX-200 for the treatment of kidney disease. The multi-centre, randomised, double-blind, placebo-controlled study is testing the drug’s efficacy and safety in patients with focal segmental glomerulosclerosis (FSGS) who are […]
ECS Botanics Achieves Positive Cash Flow Breakthrough in September Quarter
ECS Botanics Holdings (ASX: ECS) has delivered a positive net operating cash flow of $140,000 for the three months to end September, representing an improvement of $1.6 million on the June quarter and $900,000 on the same time last year. The company’s direct-to-consumer (B2C) strategy generated strong results to complement its established business-to-business (B2B) and export […]